Phthalylsulfathiazole - Misplaced Pages

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 17:32, 2 September 2011 (Updating {{drugbox}} (changes to watched fields - updated 'ChemSpiderID_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacology|er). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 17:32, 2 September 2011 by CheMoBot (talk | contribs) (Updating {{drugbox}} (changes to watched fields - updated 'ChemSpiderID_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacology|er)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound

Phthalylsulfathiazole
Clinical data

AHFS/Drugs.com	International Drug Names
ATC code	A07AB02 (WHO)
Identifiers
IUPAC name 2-phenyl}amino)carbonyl]benzoic acid
PubChem CID	4806
UNII	6875L5852V
KEGG	D02440
CompTox Dashboard (EPA)	DTXSID8023470
ECHA InfoCard	100.001.480
Chemical and physical data
Formula	C₁₇H₁₃N₃O₅S₂
Molar mass	403.43222 g/mol g·mol
(verify)

Phthalylsulfathiazole belongs to the group of drugs called sulfonamides. The drug is a broad spectrum antimicrobial that can treat different types of infections including intestinal. The mechanism of action depends is based on competitive antagonism with para-aminobenzoic acid and inhibition of dihydropteroate synthetase activity, that in turn leads to impaired synthesis of dihydrofolic acid and as a result its active metabolite that is necessary for the synthesis of purine and pyrimidine.

The drug is indicated in treatment of dysentery, colitis, gastroenteritis and intestinal surgery. Adverse effects may include allergic reactions, vitamin B insufficiency, agranulocytosis and aplastic anemia.

v t e Antidiarrheals, intestinal anti-inflammatory and anti-infective agents (A07)
Rehydration	Oral rehydration therapy
Intestinal anti-infectives	Antibiotics Amphotericin B Colistin Fidaxomicin Kanamycin Natamycin Neomycin Nystatin Paromomycin Polymyxin B Rifaximin Streptomycin Vancomycin Sulfonamides Phthalylsulfathiazole Succinylsulfathiazole Sulfaguanidine Nitrofuran Nifuroxazide Nifurzide Imidazole Miconazole Arsenical Acetarsol Oxyquinoline Broxyquinoline
Intestinal adsorbents	Charcoal Bismuth (including bismuth subsalicylate, known as Pepto-Bismol) Pectin Kaolin Crospovidone Attapulgite Diosmectite
Antipropulsives (opioids)	Opium tincture (laudanum) Codeine Morphine Camphorated opium tincture (paregoric) crosses BBB: Diphenoxylate (+atropine) Difenoxin does not cross BBB: Eluxadoline Loperamide (+simethicone)
Intestinal anti-inflammatory agents	corticosteroids acting locally Prednisolone Hydrocortisone Prednisone Betamethasone Tixocortol Budesonide Beclometasone antiallergic agents, excluding corticosteroids Cromoglicic acid Aminosalicylates Sulfasalazine Mesalazine Olsalazine Balsalazide
Antidiarrheal micro-organisms	Escherichia coli Saccharomyces boulardii
Other antidiarrheals	Albumin tannate Bismuth subsalicylate Ceratonia Crofelemer Octreotide Racecadotril Kaopectate
WHO-EM Withdrawn from market Clinical trials: Phase III Never to phase III

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

Categories: